Baff-R Car-T
WM
Institute of Hematology & Blood Diseases Hospital, ChinaCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
59 Active assets in the WM cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Fred Hutchinson Cancer Center | Phase 2 | BBB |
Cyclophosphamide Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | BBB |
Fludarabine Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | BBB |
PREDNISONE TABLETS BeOne Medicines | Phase 2 | BBB |
Inno-206 BeOne Medicines | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
Baff-R Car-T is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →